Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group of symptoms but includes abdominal pain and disturbed defecation. IBS is divided into several subtypes including:
• Diarrhoea predominant (IBS-D)
• Constipation predominant (IBS-C)
• Alternating (IBS-A)
• Pain predominant.
These subtypes are identified by the dominant symptoms that the patient experiences.
This report provides the current prevalent population for Irritable Bowel Syndrome across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Irritable Bowel Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Irritable Bowel Syndrome include:
• Abdominal pain
• Abdominal cramping
• Bloated/Gassy feeling
• Gas (Flatulence)
• Diarrhoea
• Constipation
• Mucus in stools
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Irritable Bowel Syndrome market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Irritable Bowel Syndrome and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Irritable Bowel Syndrome prevalent population.
• Identify sub-populations within Irritable Bowel Syndrome which require treatment.
• Gain an understanding of the specific markets that have the largest number of Irritable Bowel Syndrome patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line prevalence for Irritable Bowel Syndrome
• Features of Irritable Bowel Syndrome patients
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Rome II Diagnostic Criteria for IBS
• Rome III Diagnostic Criteria for IBS
• Prevalence of IBS, total (000s)
• Prevalence of IBS, males (000s)
• Prevalence of IBS, females (000s)
• IBS Classification, total (000s)
• IBS by Rome II Classification, total (000s)
• Rome III Classification, total (000s)
• Confirmation of IBS diagnosis, total (000s)
• Abdominal symptoms, total (000s)
• Non-colonic symptoms, total (000s)
• Other gastrointestinal disease, total (000s)
• Food intolerance, total (000s)
• Major depressive disorder, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• USA Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• Canada Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• Canada Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• France Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• France Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• Germany Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• Germany Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• Italy Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• Italy Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• Spain Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• Spain Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• UK Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• UK Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• Brazil Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• Brazil Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• Japan Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• Japan Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• India Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• India Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• China Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• China Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
• Russia Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, males (000s)
• Russia Prevalence of Irritable Bowel Syndrome by 5-yr age cohort, females (000s)
